Utilization of antihypertensive drugs in obesity-related hypertension: a retrospective observational study in a cohort of patients from Southern Italy.
Mauro CataldiOrnella di GeronimoRossella TrioAntonella ScottiAndrea MemoliDomenico CaponeBruna GuidaPublished in: BMC pharmacology & toxicology (2016)
Our data show that no first choice protocol seems to be adopted in clinical practice for the treatment of obesity-related hypertension. Importantly, physicians do not seem to differentiate drug use according to the severity of obesity or to the presence of metabolic syndrome or to avoid drugs known to detrimentally affect body weight and metabolic profile in general population.
Keyphrases
- metabolic syndrome
- insulin resistance
- blood pressure
- body weight
- weight loss
- type diabetes
- high fat diet induced
- end stage renal disease
- weight gain
- clinical practice
- newly diagnosed
- ejection fraction
- uric acid
- adipose tissue
- chronic kidney disease
- randomized controlled trial
- primary care
- cardiovascular risk factors
- peritoneal dialysis
- electronic health record
- prognostic factors
- body mass index
- skeletal muscle
- physical activity
- patient reported outcomes
- hypertensive patients
- artificial intelligence
- replacement therapy